CDKN2A and head and neck squamous cell carcinoma: This study sought to elucidate the prognostic implications of CDKN2A mutations in patients with recurrent or metastatic HNSCC, complemented by a nuanced subgroup analysis focusing on those undergoing immunotherapy.